Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment



Rating:

Share or cite this content

Citations should be made in the following way:
A. Rathnapala (Minuwangoda, Sri Lanka). Anti-synthetase syndrome associated Interstitial Lung Disease (ASS-ILD): clinical heterogeneity and outcome. 885

Member's Comments

No comment yet.

Related content which might interest you: Anti-synthetase syndrome associated Interstitial Lung Disease (ASS-ILD): Clinical, serological and radiological heterogeneity Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Clinical features and prognosis of 108 patients with lymphangioleiomyomatosis Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Verification of genetic associations with Scleroderma associated Interstitial Lung Disease Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019 Annual changes in pulmonary function are independent prognostic factors for the patients with chronic hypersensitivity pneumonia Source: International Congress 2014 – ILDs 3 Year: 2014 Lymphangioleiomyomatosis in TOSCA - TuberOus SClerosis registry to increAse disease awareness Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Management of spontaneous pneumothorax in patients with or without Birt-Hogg-Dubé syndrome Source: International Congress 2014 – ILDs 1 Year: 2014 Pregnancy course in patients with interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 2 Year: 2014 A large cohort study of clinical outcomes and prognostic predictors in patients with acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2014 – IPF and surroundings Year: 2014 Does CRP predicts severity of hospitalized patients with diffuse interstitial lung disease? Source: International Congress 2014 – ILDs 5 Year: 2014 Clinical course and outcome of vasculitis related interstitial lung disease Source: International Congress 2014 – ILDs 2 Year: 2014 The prognostic factor in patients with myositis-associated interstitial lung disease Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Desquamative interstitial pneumonia in a Danish cohort, treatment response and outcome Source: International Congress 2014 – ILDs 2 Year: 2014 Early pulmonary phenotype in Hermansky-Pudlak syndrome: Analysis of the chILD-EU registry Source: International Congress 2016 – Paediatric bronchology I Year: 2016 Mutation alone does not predict the clinical course of surfactant protein C deficiency in children Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Does the BTNL2 genotype influence the course of disease in Danish sarcoidosis patients? Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting Source: International Congress 2014 – ILDs 6 Year: 2014 LATE-BREAKING ABSTRACT: Current management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Pulmonary manifestations in rheumatoid arthritis: A hospital based descriptive study Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Cryptogenic organising pneumonia focusing on its prognostic determinants Source: International Congress 2014 – ILDs 4 Year: 2014